ClinicalTrials.gg
RecruitingNCT03709914Pediatric_PKUpdated Sep 15, 2023

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

A Phase 1 interventional study of ZTI-01 100 mg/kg and ZTI-01 75 mg/kg in Pediatric ALL, sponsored by Nabriva Therapeutics AG. Recruiting at 5 sites in United States. Open to participants aged Up to 11 Years. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Nabriva Therapeutics AG · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled May 2018, registered Oct 2018).
  • Started May 2018; still recruiting 8 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
Up to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 171 open to participants now, 277 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Planned enrollment
847th of 1,269
21 · median 35
Started
2018
with 38 others
Phase 1
500 of 1,545
49 open now
Primary completion
2025-12
later than 55 of 275 live
Registered
1,226th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 847th largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2018, is one of 500 in phase 1, reaches primary completion later than 55 of the 275 other live ones, and was the 1,226th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 473 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

171 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (69%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

Phase 1 study, a single dose of ZTI-01 given to pediatric subjects (under 12 years of age) who require antibiotic therapy to see what the body does to the drug (pharmacokinetics) and to compare if these effects are similar to those observed in adults at a 6g ZTI-01 dose. Study will help establish pediatric dosing in younger children by age cohort. This is a multiple-center, open-label, PK study of ZTI-01 (fosfomycin for injection) single dose scaled by allometric weight-modeling from an adult ZTI-01 dose of 6 grams. Eligible subjects must be receiving standard of care antibiotics for proven or suspected bacterial infection or for peri-operative prophylaxis surgery (in or out of hospital).

Read the detailed description

Based on pre-dose weight on Day -1, subjects weighing within the 3rd to \< 97th percentile based on age - will receive a single, weight adjusted dose of ZTI-01 via continuous IV infusion or syringe pump over a 1- hour (+10 min) period. Pediatric subjects participating in this study will be assigned to one of three cohorts based on age:

Cohort 1: ≥ 6 years to \<12 years (n=6 PK evaluable subjects) Cohort 2: ≥ 2 years to \<6 years (n=6 PK evaluable subjects)

Cohort 3: Birth to \< 2 years (n=9 PK evaluable subjects), split into 3 subgroups:

(3a) Birth (defined as full term: 37 weeks of gestations or greater) to \< 3 mos, (3b) ≥ 3 mos to \< 6 mos, (3c) ≥ 6 mos to \< 24 months

Cohorts 1 and 2 will be enrolled first with safety and PK data evaluated before enrolling the youngest Cohort 3. Blood for fosfomycin concentration measurement will be collected throughout the study. Safety will be assessed by monitoring adverse and serious adverse events based on medical history, vital signs, ECG, laboratory assessment and physical examination.

03

Conditions studied

  • Pediatric ALL

Keywords

  • Pediatric PK
04

Who can participate

Ages eligible
Up to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed consent/assent
  • Male or female subjects aged from Birth (defined as full term: 37 weeks of gestation or greater) but less than 12 years old
  • Hospitalized, currently receiving antibacterial treatment for confirmed or suspected bacterial infection
  • If of , agrees to avoid becoming pregnant or impregnating a partner from the time of consent through 24 hours after completion of study drug administration
  • Has sufficient intravascular access to receive study drug through peripheral or central line

Exclusion criteria

Exclusion Criteria:

  • Has history of known allergy, , or intolerance to oral or intravenous fosfomycin
  • Screening serum (ALT) or aspartate aminotransferase (AST) >3x or total >2x ULN
  • Female is post onset of menarche and currently pregnant, or breast feeding, or has a positive serum or urine β-human chorionic gonadotropin (β-hCG) pregnancy test
  • Impaired renal function at screening based on the Revised Schwartz Formula using actual body height
  • Known infection with immunodeficiency virus (), virus, or virus
  • Other laboratory tests, obtained as standard of care, that are outside the normal limits, considered by the Investigator, to be
  • Have surgery scheduled during collection period of plasma for fosfomycin concentrations
  • Weighs outside of the 3rd to less than \<97th percentile based on age
  • History of a seizure disorder requiring ongoing treatment with anticonvulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years
  • Is currently participating in or has participated in an interventional clinical trial with an compound or device within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) of administration of the study drug
  • Has enrolled previously in the current trial or has received ZTI-01 or fosfomycin (IV or oral) for any other reason within the last 30 days
  • Is expected to survive less than 72 hours after completion of study drug administration
  • Plans to use cardiopulmonary bypass, extracorporeal membrane oxygenation, hemodialysis, or peritoneal dialysis during the study
  • Clinically significant abnormalities on the ; or have or be at risk for major cardiac events or dysfunction including prolongation, clinically unstable cardiac disease, receipt within 24 hours before the start of study drug of a medication that is labelled to prolong the QT interval, and for breastfed infant subjects only - receipt by the subject's mother within 24 hours before the start of study drug of a medication that is labelled to prolong the QT interval
  • Planned blood transfusion within 24 hours of study drug administration or expected before the end of the PK sampling, or has had significant blood loss (≥5% of total blood volume) within 4 weeks before the screening visit
  • Any condition that, in the opinion of the PI, would compromise the safety of the subject or the quality of the data
  • Subject or caregiver/parent is unable or unwilling to adhere to the study-specified procedures and restrictions
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    ZTI-01 Cohort 1 ≥ 6 to <12 years of age

    ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

    Drug: ZTI-01 100 mg/kg

  • Experimental
    ZTI-01 Cohort 2 ≥ 2 to <6 years of age

    ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

    Drug: ZTI-01 100 mg/kg

  • Experimental
    ZTI-01 Cohort 3a Birth to < 3 mos of age

    ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

    Drug: ZTI-01 75 mg/kg

  • Experimental
    ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age

    ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

    Drug: ZTI-01 100 mg/kg

  • Experimental
    ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age

    ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to \< 97th percentile for age

    Drug: ZTI-01 100 mg/kg

Interventions

  • DrugZTI-01 100 mg/kg

    Drug page: Fosfomycin sodium

    ZTI-01 intravenous (IV)

    Also known as: IV fosfomycin, fosfomycin disodium, fosfomycin for injection

  • DrugZTI-01 75 mg/kg

    Drug page: Fosfomycin sodium

    ZTI-01 intravenous (IV)

    Also known as: IV fosfomycin, fosfomycin disodium, fosfomycin for injection

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve (AUC) after a single dose of ZTI-01

    By age cohort, determine the ZTI-01 pharmacokinetic area under the plasma concentration-time curve

    Time frame: From time end of 1-hour infusion on Day 1, up to 8-12 hours post infusion on Day 1

Secondary outcomes

  1. Safety: Treatment Emergent Adverse Events (TEAE)

    Number and Incidence of TEAEs by age cohort

    Time frame: Baseline (start of dosing) through end of study follow-up (Day 2)

  2. Maximum concentration (Cmax) after a single dose of ZTI-01

    By age cohort, determine the ZTI-01 pharmacokinetic maximum concentration (Cmax)

    Time frame: From time end of 1-hour infusion on Day 1, up to 8-12 hours post infusion on Day 1

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Dec 2025, 91 months after the start.

Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 91 months is above that.

Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2018
First posted
Oct 17, 2018
StartActual
May 24, 2018
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 10, 2026
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03709914
Lead sponsor
Nabriva Therapeutics AG
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
May 24, 2018
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 10, 2026 (estimated)
Last update
Sep 15, 2023

Study contacts

Steve Gelone
Contact
Steve.Gelone@nabriva.com
6108166641
John S Bradley, MD
principal investigator · Rady Children's Hospital / Department of Pediatrics, University of California, School of Medicine
Jennifer Schranz, MD
study chair · Nabriva Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosfomycin sodium

Start the discussion